A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ac Immune Sa stock. As of the latest transaction made, Citadel Advisors LLC holds 26,800 shares of ACIU stock, worth $95,140. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,800
Previous 12,900 107.75%
Holding current value
$95,140
Previous $51,000 98.04%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.99 - $4.2 $38,875 - $54,608
-13,002 Reduced 37.35%
21,806 $82,000
Q2 2024

Aug 14, 2024

SELL
$2.29 - $4.87 $59,365 - $126,249
-25,924 Reduced 42.69%
34,808 $138,000
Q1 2024

May 15, 2024

BUY
$2.66 - $4.87 $161,547 - $295,764
60,732 New
60,732 $179,000
Q3 2023

Nov 14, 2023

BUY
$2.77 - $3.38 $3,038 - $3,707
1,097 New
1,097 $3,000
Q1 2023

May 15, 2023

SELL
$2.13 - $2.49 $349,102 - $408,106
-163,898 Reduced 98.11%
3,165 $7,000
Q4 2022

Feb 14, 2023

BUY
$1.72 - $3.12 $287,348 - $521,236
167,063 New
167,063 $340,000
Q4 2021

Feb 14, 2022

SELL
$4.83 - $7.56 $50,362 - $78,828
-10,427 Reduced 28.93%
25,613 $126,000
Q3 2021

Nov 15, 2021

BUY
$6.2 - $8.34 $88,492 - $119,036
14,273 Added 65.57%
36,040 $242,000
Q2 2021

Aug 16, 2021

SELL
$6.04 - $8.37 $90,763 - $125,775
-15,027 Reduced 40.84%
21,767 $172,000
Q1 2021

May 17, 2021

BUY
$5.32 - $8.96 $68,223 - $114,903
12,824 Added 53.5%
36,794 $280,000
Q3 2020

Nov 16, 2020

BUY
$4.78 - $9.06 $114,576 - $217,168
23,970 New
23,970 $117,000
Q2 2020

Aug 14, 2020

SELL
$6.57 - $8.3 $282,155 - $356,451
-42,946 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$4.24 - $9.89 $166,301 - $387,905
-39,222 Reduced 47.73%
42,946 $297,000
Q4 2019

Feb 14, 2020

SELL
$4.56 - $8.78 $174,050 - $335,123
-38,169 Reduced 31.72%
82,168 $700,000
Q3 2019

Nov 14, 2019

SELL
$4.8 - $5.89 $221,232 - $271,470
-46,090 Reduced 27.69%
120,337 $595,000
Q2 2019

Aug 14, 2019

BUY
$4.72 - $5.88 $200,194 - $249,394
42,414 Added 34.2%
166,427 $924,000
Q1 2019

May 15, 2019

SELL
$3.65 - $11.68 $1.19 Million - $3.8 Million
-325,525 Reduced 72.41%
124,013 $0
Q4 2018

Feb 14, 2019

BUY
$7.35 - $11.7 $1.21 Million - $1.93 Million
164,701 Added 57.82%
449,538 $4.25 Million
Q3 2018

Nov 13, 2018

BUY
$7.88 - $16.45 $2.12 Million - $4.43 Million
269,094 Added 1709.29%
284,837 $0
Q1 2018

May 11, 2018

SELL
$10.34 - $13.78 $639,518 - $852,279
-61,849 Reduced 79.71%
15,743 $163,000
Q3 2017

Nov 09, 2017

BUY
$7.06 - $11.2 $547,799 - $869,030
77,592
77,592 $877,000

Others Institutions Holding ACIU

About AC Immune SA


  • Ticker ACIU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,413,504
  • Market Cap $296M
  • Description
  • AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectiv...
More about ACIU
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.